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A general problem in biosurveillance is ﬁnding appropriate aggregates of elemental data to monitor for the detection of disease out-
breaks. We developed an unsupervised clustering algorithm for aggregating over-the-counter healthcare (OTC) products into categories.
This algorithm employs MCMC over hundreds of parameters in a Bayesian model to place products into clusters. Despite the high
dimensionality, it still performs fast on hundreds of time series. The procedure was able to uncover a clinically signiﬁcant distinction
between OTC products intended for the treatment of allergy and OTC products intended for the treatment of cough, cold, and inﬂuenza
symptoms.
 2007 Elsevier Inc. All rights reserved.
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A fundamental problem in the analysis of biosurveil-
lance data is the need to aggregate data collected from
care-seeking behavior into well-deﬁned categories suitable
for routine monitoring. For example, it is common to
aggregate data about individual emergency department
(ED) or outpatient physician visits into daily counts of vis-
its for respiratory complaints for particular geographical
regions such as zip codes [1–6]. Outbreak detection algo-
rithms then analyze, for example, the time series of daily
counts of ED visits for respiratory syndrome.
Biosurveillance systems also monitor aggregates or cat-
egories of over-the-counter healthcare (OTC) products
for signs of outbreaks of various diseases. There is evidence
that monitoring certain categories of products can provide
early warning of certain disease outbreaks. Examples
include cold remedies—but not antipyretics—for Inﬂuenza
B outbreaks [7], pediatric electrolytes for seasonal out-
breaks of respiratory and gastrointestinal illness in children1532-0464/$ - see front matter  2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.jbi.2007.03.008
* Corresponding author. Fax: +1 412 802 6803.
E-mail address: garrick@cbmi.pitt.edu (G.L. Wallstrom).[8], and OTC diarrhea remedies for waterborne Cryptospo-
ridium outbreaks [9–11].
However, there has been little research into which aggre-
gates of biosurveillance data are best for the monitoring of
outbreaks of various diseases. There has been minimal dis-
cussion of even the criteria for choosing the best aggre-
gates. Ultimately, the choice of aggregate is only one
factor that determines the overall utility of a biosurveil-
lance system in terms of lives saved, morbidity prevented,
and the cost of the system. Given the near-impossibility
of isolating all other factors (statistical outbreak detection
algorithms, biosurveillance personnel, outbreak character-
istics, etc.), measuring the utility of aggregates in this way
is impractical (for certain, we cannot conduct randomized,
controlled trials). One obvious criterion for choosing
aggregates is outbreak detection performance: aggregates
that provide earlier, more sensitive detection of outbreaks
with fewer false alarms are better than aggregates that pro-
vide later, less sensitive detection with more false alarms.
However, there is no guarantee that aggregates better for
the detection of past inﬂuenza outbreaks, for example, will
necessarily be better for detecting future inﬂuenza out-
breaks. Additionally, users of biosurveillance systems also
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alarms that analysis of biosurveillance data may trigger,
and thus it is likely to be important also that aggregates
have a logical meaning according to users’ knowledge of
infectious diseases.
The typical approach to forming aggregates, including
categories of OTC products, is to have human experts cre-
ate aggregates using their knowledge of infectious disease
[3,12,13]. For example, Wagner et al. divided cold relief
products into four categories based on age group (adult
vs. pediatric) and dose form (liquid vs. tablets, capsules,
and other ‘solid’ forms) [3].
This approach has limitations. There are no studies con-
ﬁrming that these distinctions are important for the detec-
tion of certain outbreaks, or that these are the only
distinctions that are relevant. Furthermore, experts can dis-
agree on the best way to form aggregates. For example,
Mikosz et al. found that two research groups used diﬀerent
deﬁnitions of the aggregate called gastrointestinal syndrome
for grouping ED visits [14]. In particular, one research
group included abdominal pain in their deﬁnition and the
other group did not.
Another approach to forming aggregates is to apply
machine learning techniques to historical data sets. These
techniques fall into two general categories: supervised clus-
tering and unsupervised clustering. The main advantage of
supervised clustering is that it can form clusters speciﬁc to
particular disease outbreaks, such as inﬂuenza outbreaks.
The main limitations are that it requires multiple outbreaks
to avoid overﬁtting, and obtaining gold standard data from
multiple outbreaks is diﬃcult. The advantage of unsuper-
vised clustering is that gold standard data from multiple
outbreaks are not required. Although its main limitation
is that the clusters it forms may be irrelevant, it does have
the ability to ﬁnd relevant clusters in many domains other
than biosurveillance. In the remainder of this paper, our
focus is unsupervised clustering.
The only study to apply unsupervised clustering to the
problem of forming categories of OTC products (of which
we are aware) is one by Magruder et al. [15]. They ﬁrst
grouped products together into 61 low-level categories
qualitatively based on age group (adult, pediatric, infant),
dose form (e.g., tablet, liquid, inhaler), and indication
(e.g., fever, cough, allergy). They then formed time series
for each of the 61 low-level categories and used standard
hierarchical clustering techniques to group them into 16
product categories. They used a distance metric to guide
the clustering, which they computed as follows:
log P ðc1 þ c2jM1ÞÞ  logðP ðc1; c2jM2Þð Þ;
where c1 and c2 are two categories of OTC products and
M1 and M2 are statistical models of the aggregated sales
of the categories (M1) and individual sales of the categories
(M2). Thus, the lower the distance metric, the more similar
the aggregated sales were to the sales of each individual
category. They chose an arbitrary threshold for the dis-
tance metric, leading to a ﬁnal set of 16 product categories.The procedure of Magruder et al. has several limita-
tions. First, it requires a qualitative step that employs
domain expertise to construct groupings of OTC products
into low-level categories based on age group, dose form,
and indication. In addition to the eﬀort required in this
step, it also means that their procedure cannot ﬁnd subsets
of the low-level categories that might be interesting or more
naturally cluster together but are unanticipated by experts.
For example, it may be that smokers with a chronic cough
typically buy diﬀerent cough syrup products than people
with inﬂuenza. But since adult cough syrup is already a
low-level category, the method would not be able to dis-
cover the distinction, if it exists, or rule it out if it does
not exist. A second limitation of the procedure is its use
of a stepwise hierarchical clustering procedure. Because
of its stepwise nature, hierarchical clustering fails to evalu-
ate many possible clusters, and thus it may miss better
clusters.
We addressed these limitations by developing an unsu-
pervised time-series clustering procedure that uses individ-
ual product time series as input and uses a stochastic
clustering procedure to explore more fully the space of pos-
sible groupings. One diﬃculty with using time series for
individual products as input is that manufacturers bring
new products to market and phase out older products reg-
ularly. As we shall discuss, our method addresses this diﬃ-
culty. Another diﬃculty is that promotions may
dramatically aﬀect individual product sales and our
method handles promotional eﬀects as well. In this paper,
we describe the unsupervised clustering method and an
experiment we conducted to assess its validity.2. The unsupervised clustering procedure
The unsupervised clustering procedure uses Markov
chain Monte-Carlo simulation to estimate parameters of
a Bayesian clustering model. Although our underlying
model is Bayesian, we are primarily interested in obtaining
a single clustering of time series rather than exploring the
full posterior distribution over the parameters of the
model.
2.1. Bayesian clustering model
Suppose that there are n time series, X1(Æ), . . . ,Xn(Æ), each
of which is deﬁned on a grid t = 1, . . . ,m and has non-neg-
ative integer values. Each time series belongs in exactly one
of C clusters. The map from time series to cluster is given
by d, that is, d(j) = i when time series j is in cluster i. Each
cluster has a parameter that represents the average shape
for time series that belong to the cluster. For cluster i, this
shape parameter is denoted by ki(Æ), and is deﬁned on the
grid t = 1, . . . ,m. As ki only represents the shape of time
series in cluster i, ki is constrained to sum to unity,Pm
t¼1kiðtÞ ¼ 1. Further, because the time series
X1(Æ), . . . ,Xn(Æ) have non-negative values, ki(t)P 0.
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healthcare products is handling drastic changes in sales vol-
ume. It is not uncommon for a product to have virtually no
sales for several months before a sharp increase in sales.
Similarly, product sales sometimes drop oﬀ substantially
if the product is taken oﬀ the market by the producer, or
taken oﬀ the shelf by a retailer. Hence, two products could
have very similar sales histories for 10 months, but in the
remaining 2 months, sales of one of the products may
decrease dramatically. As our clusters are trying to ﬁnd
products with similar sales histories, we would not want
those two products to end up in two diﬀerent clusters sim-
ply due to the loss in sales over the last 2 months. We there-
fore use a change-point model to accommodate such time
series that have a dominant interval that may be sur-
rounded on one or both sides by an inferior sales interval.
We model Xj(t), for j = 1, . . . ,n and t = 1, . . . ,m as inde-
pendent Poisson random variables. Let lj(t) denote the
mean of Xj(t). For t in the dominant interval [sj,ej], lj(t)
is equal to a factor aj times the cluster shape at time
t, kd(j)(t). For t outside of the dominant interval [sj,ej],
lj(t) is equal to hj. More formally, let k = (k1, . . . ,kC),
a = (a1, . . . ,an), d = (d1, . . . ,dn), h = (h1, . . . ,hn), s =
(s1, . . . , sn), and e = (e1, . . . ,en). Then
X jðtÞjk; a; d; h; s; e indep:PoisðljðtÞÞ; where
ljðtÞ ¼
ajkdðjÞðtÞ; sj 6 t 6 ej
hj; t < sj or t > ej

The observed data in the above model are the time series
X = (X1, . . . ,Xn). We assume that the number of clusters
C is known. The remaining parameters, k,a,d,h, s, and e
are all unknown. To complete the model, we must specify
our prior distributions on k,a,d,h, s, and e.
Prior distribution of k. The cluster shapes, k1, . . . ,kC are
independent a priori with Dirichlet(1,. . .,1) prior distribu-
tions. The Dirichlet(1,. . .,1) distribution is a uniform distri-
bution over the space of non-negative functions that sum
to one.
Prior distribution of a. The scale factors a1, . . . ,an are
independent a priori, and we use the non-informative and
improper prior distribution p(aj)  1 for each j. Observe
that aj will approximately equal the sum of the time series




dj; hj; sj ¼ 1; ej ¼ m ¼ aj. As
Pm
t¼1X jðtÞ is often not known
(at least in our applications) and varies dramatically across
time series, we use an improper prior to avoid placing too
little prior weight around
Pm
t¼1X jðtÞ.
Prior distribution of d. The cluster identiﬁers
d(1), . . . ,d(n) are independent, and identically distributed
uniformly on {1, . . . ,C}.
Prior distribution of h. We set h1, . . . ,hn to be indepen-
dent and identically distributed gamma variates with shape
parameter 4 and rate 8. Under this distribution, the prior
expected value of hj is 0.5 and the standard deviation is
0.25. These values were chosen based on the role of hj,
the mean of time series j during its inferior intervals.Prior distribution of s and e. The prior for the start and
end time points for the dominant interval of time series j is
slightly more complicated because the start and end points
are necessarily correlated due to their constraint that
sj 6 ej. We use the prior
pðsj; ejÞ ¼ 2m ðmþ 1Þ for 1 6 sj 6 ej 6 m:
Under this prior, the marginal priors for sj and ej are
pðsjÞ ¼ 2ðm sj þ 1Þmðmþ 1Þ for 1 6 sj 6 m; and
pðejÞ ¼ 2ejmðmþ 1Þ for 1 6 ej 6 m
The above prior implies that sj is more likely to be near 1
than near m/2, the middle. Similarly, ej is more likely to
be near m than near m/2. This prior is consistent with
our intention that sj should only move away from 1 when
there is strong evidence to do so, and ej should only move
away from m when there is strong evidence to support such
a move.
Finally, we note that the above model is quite large. In
fact, there are C(m  1) + 5n free parameters in the model.
If there are 100 time series of 100 time-points each, and
four clusters, then there are 4 · 99 + 5 · 100 = 896 free
parameters in the model.
2.2. Markov chain Monte-Carlo
Markov chain Monte-Carlo is a popular method for
estimating parameters in Bayesian models [16,17]. In this
approach, we generate a large sample of values from the
posterior distribution. The sample can then be used to
obtain point estimates for parameters (for example, the
sample average is an estimate for the posterior mean), or
to create credible regions, which are the Bayesian analogs
of conﬁdence regions.
It is often the case, however, that the full posterior dis-
tribution over all parameters in the model is unwieldy. The
Gibbs sampler is one approach for sampling from a multi-
dimensional distribution. In this approach, each parameter
is sampled successively from the conditional posterior dis-
tribution given the remaining parameters.
The Gibbs sampling routine that we used to ﬁt the
model described above has four main components: sam-
pling a, sampling d, sampling h, and sampling s and e.
Sampling a. The conditional posterior distribution of aj
given the remaining parameters is gamma, speciﬁcally,
ajjX; k; aj; d; h; s; e  Cð
Pej
t¼sjX jðtÞ þ 1;
Pej
t¼sjkdðjÞðtÞÞ, where
aj denotes the vector of a parameters, excluding aj.
Sampling d. The conditional posterior probability that
d(j) = i given the remaining parameters is proportional toQej
t¼sje
ajkiðtÞkiðtÞX jðtÞ. We can compute this quantity for each
i, and then divide these values by their sum to obtain the
conditional posterior probabilities.
Sampling h. The conditional posterior distribution of hj
given the remaining parameters is gamma, speciﬁcally,
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P
t62½sj;ejX jðtÞ þ 4;m ðej  sj þ 1Þþ8Þ, where hj denotes h excluding hj.
Sampling s and e. The conditional posterior distribution










t 62½sj ;ej 
X jðtÞ
j :
To sample from this distribution, we use Metropolis-Has-
tings sampling [16]. Metropolis-Hastings algorithm is often
used when only the functional form of the conditional pos-
terior distribution is known. The idea is that instead of
sampling from the actual conditional posterior distribu-
tion, we sample from a proposal distribution that we can
sample from easily, and then compute an acceptance prob-
ability that we use to determine whether the sampled value
should be kept or rejected. Here we use the prior distribu-
tion for (sj, ej) as the proposal distribution.
In order to signiﬁcantly reduce the computation time
required to ﬁt the model, we do not sample from the con-
ditional posterior distribution of k. Instead, we set k to be
equal to the mode of its conditional posterior distribution.
This computational shortcut does cause the model to be
overﬁt. We adopted this approach, however, because we
are primarily interested in ﬁnding a single good clustering,
rather than the full posterior over the model parameters,
and the time savings is substantial.3. Evaluation of procedure
We evaluated our procedure by applying it to a histori-
cal data set of OTC product sales. Our hypothesis was that
the procedure could ﬁnd categories that had clinically rele-
vant distinctions.3.1. Methods
We applied the procedure to a 3-year historical data set
of OTC product sales that we obtained from AC Nielsen,
Inc. This data set covered the years 2002–2004. It consists
of weekly counts of sales of individual products aggregated
over a 30-county area in western Pennsylvania. AC Nielsen
groups OTC products into its own category scheme and we
applied our procedure to the set of ‘‘cold relief’’ products in
that data set. This AC Nielsen created category includes
medications for the treatment of cold, inﬂuenza, and
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Fig. 1. Cluster shapes found when we ran the procedure on three years of Oall, there were 768 unique products that had non-zero sales
during the time period 2002–2004.
Because of the constraint to ﬁx the number of clusters,
we ran the procedure on the 768 time series a total of four
times for cluster sizes of 2, 3, 4, and 8. For each run of the
procedure, we plotted the time series of each product clus-
ter and manually analyzed the products contained in each.
Because the National Retail Data Monitor currently mon-
itors four manually created subcategories of cold-relief
products—cold-relief adult liquid, cold-relief adult tablet,
cold relief pediatric liquid, and cold relief pediatric tab-
let—we tabulated the number of products from each of
these four categories that appeared in each cluster. If we
found important distinctions among clusters in the types
of products they contained (other than age group and dose
form), we included these distinctions in the tabulation as
well.3.2. Results
When we ran the procedure constrained to two clusters,
the two clusters procedure created had very diﬀerent time
series (Fig. 1). When we observed the products in each clus-
ter, we found a predominance of products for the treatment
of allergy symptoms in cluster 2 and a predominance of
products for the treatment of cold, cough, and inﬂuenza
(or non-allergy) symptoms in cluster 1 (Table 1). The
allergy cluster (cluster 2) had signiﬁcant peaks in the spring
and fall of each year (Fig. 1), whereas the non-allergy clus-
ter (cluster 1) had signiﬁcant peaks coincident with the
inﬂuenza outbreaks of 2002–2003 and 2003–2004. Of the
28 allergy products in cluster 1, 13 had product descrip-
tions that indicated the product treated both cold and
allergy symptoms. Of the 68 non-allergy products in cluster
2, 31 contained pseudoephedrine as an active ingredient.
When we ran the procedure constrained to three clus-
ters, clusters 2 and 3 had similar time series, unlike that
of cluster 1 (Fig. 2). When tabulated according to the four
NRDM categories with an allergy vs. non-allergy distinc-
tion, clusters 2 and 3 were both non-allergy predominant
clusters whereas cluster 1 was an allergy predominant clus-
ter (Table 1).
When we ran the procedure constrained to four clusters,
clusters 1, 3, and 4 had similar time series and cluster 2 had
a diﬀerent time series (Fig. 3). When tabulated according to
the four NRDM categories with an allergy vs. non-allergy
distinction, cluster 2 was the only allergy-predominant
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TC product salesdata and constrained the procedure to ﬁnd twoclusters.
Table 1
Numbers of products of each type in each cluster
Cluster Adult Child Liquid Tablet Allergy Non-allergy Total
1 420 (83.7) 82 (16.3) 176 (35.1) 326 (64.9) 28 (5.6) 474 (94.4) 502
2 242 (91.0) 24 (9.0) 30 (11.3) 236 (88.7) 198 (74.4) 68 (25.6) 266
1 209 (90.1) 23 (9.9) 30 (12.9) 202 (87.1) 166 (71.6) 66 (28.4) 232
2 240 (83.6) 47 (16.4) 81 (28.2) 206 (71.8) 48 (16.7) 239 (83.3) 287
3 213 (85.5) 36 (14.5) 95 (38.2) 154 (61.8) 12 (4.8) 237 (95.2) 249
1 186 (83.4) 37 (16.6) 69 (30.9) 154 (69.1) 34 (15.2) 189 (84.8) 223
2 176 (89.8) 20 (10.2) 30 (15.3) 166 (84.7) 124 (63.3) 72 (36.7) 196
3 133 (86.9) 20 (13.1) 53 (34.6) 100 (65.4) 7 (4.6) 146 (95.4) 153
4 167 (85.2) 29 (14.8) 54 (27.6) 142 (72.4) 61 (31.1) 135 (68.9) 196
1 69 (90.8) 7 (9.2) 20 (26.3) 56 (73.7) 17 (22.4) 59 (77.6) 76
2 100 (87.7) 14 (12.3) 16 (14.0) 98 (86) 98 (86.0) 16 (14.0) 114
3 129 (84.9) 23 (15.1) 66 (43.4) 86 (56.6) 2 (1.3) 150 (98.7) 152
4 103 (78.0) 29 (22.0) 51 (38.6) 81 (61.4) 4 (3.0) 128 (97.0) 132
5 93 (87.7) 13 (12.3) 24 (22.6) 82 (77.4) 25 (23.6) 81 (76.4) 106
6 27 (93.1) 2 (6.9) 2 (6.9) 27 (93.1) 27 (93.1) 2 (6.9) 29
7 98 (90.7) 10 (9.3) 12 (11.1) 96 (88.9) 49 (45.4) 59 (54.6) 108
8 43 (84.3) 8 (15.7) 15 (29.4) 36 (70.6) 4 (7.8) 47 (92.2) 51
Totala 662 106 206 562 226 542 768
Numbers in parentheses are percentages of the number of products in the cluster.
a This row is the total number of products out of the 768 that have the attribute. It does not represent the sum of the column. Note that
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Fig. 2. Cluster shapes found when we constrained the procedure to ﬁnd three clusters.
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There was no predominance of products by age group or
dose-form in cluster 1 or cluster 4.
When we ran the procedure constrained to eight clus-
ters, the time series for clusters 1, 3, 4, 5, and 8 were similaraside from diﬀerences due to non-trivial inferior sales inter-
vals for products falling into clusters 1 and 8 (Fig. 4). The
remaining three clusters were fairly unique. Clusters 1, 3, 4,
5, and 8 had a predominance of non-allergy products
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Fig. 4. Cluster shapes found when we constrained the procedure to ﬁnd eight clusters.
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of allergy and non-allergy products. There was no consis-
tent age group or dose form predominance in the clusters.
4. Discussion
We created an unsupervised clustering procedure that
clusters individual time series into groups of time series
with similar temporal trends. The evaluation showed that
the procedure is capable of handling large datasets and dis-
covering clinically relevant distinctions. The execution time
of the procedure was always under one hour in our appli-
cations, and therefore the procedure is practical for use in
monitoring and updating categories of OTC products on a
monthly or even weekly basis (at present, the NRDM
receives product updates four times per year).
The primary limitation of the procedure is that it over-
ﬁts the time series data to ﬁnd the required number of clus-
ters. Hence, if the number of clusters is set too high, the
procedure will ﬁnd subtle diﬀerences in the time series that
may not be of practical importance. When we evaluated the
procedure using four clusters we found that three of the
clusters (clusters 1, 3, and 4) were very similar. Similarly,
when we ran the procedure using eight clusters, clusters
1, 3, 4, 5, and 8 are very similar aside from inferior sales
intervals at the end of cluster 1 and the beginning of cluster
8, which are explicitly modeled at the product-level
through the sj,ej, and lj parameters.
We found using the procedure that the time series for
clusters that contained predominantly allergy products
had biannual peaks in the spring and fall, whereas time ser-ies for clusters that contained predominantly non-allergy
products had peaks coincident with inﬂuenza outbreaks.
If age-group and dose-form distinctions among cold-relief
products are clinically important for seasonal respiratory
diseases such as inﬂuenza, bronchiolitis due to Respiratory
Syncytial Virus, and upper respiratory infections due to
various viruses, then they appear to be dominated by the
allergy vs. non-allergy distinction and our procedure did
not detect them. Further research is necessary to determine
whether, when using OTC cold-relief products for inﬂuenza
surveillance, it is necessary or even desirable to make dose
form and age group distinctions.
Although the evaluation study showed that clinically
relevant clusters can be found by our clustering procedure,
additional research is necessary to validate that such clus-
ters are useful for outbreak detection. Speciﬁcally, future
work should measure the outbreak detection performance
of a detection system that uses the found clusters, and com-
pare the performance to the same system using either
aggregates constructed from domain knowledge or gold
standard clinical data [18].
Overall, it appears as though seasonal respiratory dis-
eases cause similar symptoms (cough, fever, congestion)
that lead to purchase of the same products for treating
these symptoms. There was no category impacted by inﬂu-
enza that was not also impacted by other respiratory dis-
eases as evidenced by the seasonal increases in sales
before and after inﬂuenza outbreaks in all non-allergy pre-
dominant clusters. In other words, we did not ﬁnd any clus-
ter that whose sales appeared to reﬂect inﬂuenza outbreaks
alone.
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